Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$61.07 USD
-0.94 (-1.52%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $60.81 -0.26 (-0.43%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
EW 61.07 -0.94(-1.52%)
Will EW be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EW
TFX or EW: Which Is the Better Value Stock Right Now?
Edwards Lifesciences (EW) Reliance on International Sales: What Investors Need to Know
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Edwards Lifesciences (EW) Q2 Earnings Match Estimates
Other News for EW
Jefferies healthcare analyst to hold an analyst/industry conference call
Jefferies healthcare analyst to hold an analyst/industry conference call
The 1-Minute Market Report August 3, 2024
Dollar General and Philip Morris are on Goldman Sachs' list of highest conviction stock picks
Top 3 Health Care Stocks That Are Set To Fly This Quarter